Minaris Advanced Therapies vs SCTbio: CDMO Comparison
How does Minaris Advanced Therapies compare to SCTbio?
As of Aug 2026, Minaris Advanced Therapies: 3 FDA inspections (including 2 NAI, 1 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 83.1. SCTbio: no FDA inspections on file, 5 EMA/MHRA GMP certificates. Signal Score 81.6. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Minaris Advanced Therapies and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Minaris Advanced Therapies has more FDA inspections on record (3 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- SCTbio has materially broader EMA GMP coverage (5 active certificates vs 2) — stronger EU footprint.
Across the cross-modality scorecard, Minaris Advanced Therapies carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Minaris Advanced Therapies vs SCTbio
How does Minaris Advanced Therapies compare to SCTbio?
On CDMO Signal's composite Signal Score, Minaris Advanced Therapies is 83/100 and SCTbio is 82/100; Minaris Advanced Therapies has 3 FDA inspections on record vs 0 for SCTbio; European coverage is 2 active EMA+MHRA certificates for Minaris Advanced Therapies vs 5 for SCTbio. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Minaris Advanced Therapies or SCTbio?
Both Minaris Advanced Therapies and SCTbio maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Minaris Advanced Therapies has 3 FDA inspections on record; SCTbio has 0.
How do Minaris Advanced Therapies and SCTbio compare on European GMP coverage?
Minaris Advanced Therapies holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Minaris Advanced Therapies carries a Signal Score of 83/100 and SCTbio carries 82/100 — essentially tied for Minaris Advanced Therapies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →